Phase
Condition
N/ATreatment
Placebo
Loratadine
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
A histologically or cytologically documented lymphoma or multiple myeloma
Next line of therapy is autologous stem cell transplant
Adult ≥ 18 years old.
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
Life expectancy of at least 12 weeks.
The absence of any additional poorly controlled systemic disease that is directlycontraindicated or places subject at significant risk, including but not limited to:congestive heart failure, diabetes mellitus, cirrhosis or liver failure, renalfailure.
Able to adhere to study protocols and visit schedules
Exclusion
Exclusion Criteria:
Hypersensitivity or intolerance to antihistamines
Use of antihistamines within two days prior to the study period, excepting the useof single dose antihistamines during chemotherapy or blood transfusion protocols.
Recent use of G-CSF or pegfilgrastim defined as within 12 weeks of study accrual.
New and continued regular use of analgesics within the four days prior to the firstdose of G-CSF
Study Design
Connect with a study center
Cross Cancer Institute
Edmonton, Alberta T6G 1Z2
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.